콘텐츠로 건너뛰기
Merck
  • The heterozygous mutations of SLC26A8 are not the main actors for male infertility.

The heterozygous mutations of SLC26A8 are not the main actors for male infertility.

Human mutation (2022-02-20)
Mohan Liu, Jinhui Li, Yaqian Li, Chuan Jiang, Wenming Xu, Yihong Yang, Ying Shen
초록

Male infertility has become a serious health and social problem troubling approximately 15% of couples worldwide; however, the genetic and phenotypic heterogeneity of human infertility poses a substantial obstacle to effective diagnosis and therapy. A previous study reported that heterozygous mutations in solute carrier family 26 member 8 (SLC26A8, NG_033897.1) were causatively linked to asthenozoospermia. Interestingly, in our research, three deleterious heterozygous mutations of SLC26A8 were separately detected in three unrelated patients who were suffered from teratozoospermia. These three heterozygous mutations resulted in the reduction of SLC26A8 expression in transfected cells, while no disrupted expression of SLC26A8 was observed in sperm from the affected individuals. Noticeably, two of the three SLC26A8 heterozygous mutations detected in the patients were inherited from their fertile fathers. Thus, we suggested that male infertility associated with SLC26A8 mutations should be involved in a recessive-inherited pattern, considering the infertile homozygous Slc26a8 KO male mice, the contribution of heterozygous mutations in SLC26A8 in male infertility needs further deep research.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Anti-SLC26A8 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Trypsin, BRP, European Pharmacopoeia (EP) Reference Standard